

Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Progressed on First Line Therapy

EGFR +

ALK +

RET+

KRAS G12 C+

MET/RET/ROS1

ROS1+

Progressed On EGFR TKI

EGFR 19 or 21

LUN0133
Phase Ib Study to Eluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combo w/ Either Osimertinib in Unresectable Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, OR w/ Cetuximab in Metastatic Colorectal Cancer
PI: Myall
Sponsor: Genentech, Inc.

LUN0112
[Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC](#)
PI: Wakelee
Sponsor: NCCN

LUN0128
Phase II Open-Label Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Advanced or Metastatic Solid Tumors including EGFR-mutated NSCLC
PI: Neal
Sponsor: Janssen Research & Development, LLC

LUN0122
[Phase I/Ib JNJ-73841937 \(Lazertinib\) Monotherapy or in Combo w/ JNJ-61186372 in Advanced NSCLC](#)
PI: Neal
Sponsor: Janssen Research

LUN0130
Phase I/II Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
PI: Neal
Sponsor: Nuvalent, Inc.

LUN0123
[Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Advanced Solid Tumors with RET Gene Abnormalities](#)
PI: Wakelee
Sponsor: Helsinn Healthcare SA

None at This Time.

ECOG-ACRIN-EA5191
[Randomized Phase II Trial of Cabozantinib & Cabozantinib + Nivolumab vs Standard Chemotherapy in Previously Treated Non-Squamous NSCLC](#)
PI: Neal
Sponsor: ECOG-ACRIN

LUN0129
Phase I/II Study of Highly Selective ROS1 Inhibitor NVL-520 in Advanced NSCLC and Other Solid Tumors (ARROS-1)
PI: Neal
Sponsor: Nuvalent, Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study

- Optional Path
- Trial Posting
- Enrollment on Hold

- Extension Study
- Immunotherapy